Squarepoint
RYTM icon

Squarepoint’s Rhythm Pharmaceuticals RYTM Stock Holding History

Squarepoint’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47M Buy
422,921
+159,953
+61% +$14.5M 0.05% 355
2026
Q1 		$22.9M Buy
262,968
+230,139
+701% +$22.4M 0.03% 632
2025
Q4 		$3.51M Buy
+32,829
New +$3.48M ﹤0.01% 1684
2025
Q2 		– Sell
-24,413
Closed -$1.29M – 4982
2025
Q1 		$1.29M Buy
+24,413
New +$1.35M ﹤0.01% 2443
2024
Q3 		– Sell
-26,243
Closed -$1.08M – 4622
2024
Q2 		$1.08M Sell
26,243
-82,512
-76% -$3.29M ﹤0.01% 2502
2024
Q1 		$4.71M Buy
108,755
+93,405
+609% +$4.09M 0.01% 1487
2023
Q4 		$706K Buy
+15,350
New +$484K ﹤0.01% 2764
2023
Q2 		– Sell
-105,975
Closed -$1.89M – 3942
2023
Q1 		$1.89M Buy
105,975
+40,837
+63% +$1.03M 0.01% 1446
2022
Q4 		$1.9M Buy
65,138
+7,144
+12% +$184K 0.01% 1398
2022
Q3 		$1.42M Buy
57,994
+13,830
+31% +$257K 0.01% 1537
2022
Q2 		$183K Buy
44,164
+29,602
+203% +$162K ﹤0.01% 2502
2022
Q1 		$168K Buy
+14,562
New +$128K ﹤0.01% 2515
2021
Q3 		– Sell
-20,611
Closed -$404K – 3365
2021
Q2 		$404K Sell
20,611
-50,933
-71% -$1.06M ﹤0.01% 2295
2021
Q1 		$1.52M Buy
71,544
+21,203
+42% +$615K 0.01% 1238
2020
Q4 		$1.5M Buy
50,341
+40,102
+392% +$1.02M 0.01% 1085
2020
Q3 		$222K Buy
+10,239
New +$235K ﹤0.01% 2016
2020
Q1 		– Sell
-36,077
Closed -$828K – 2417
2019
Q4 		$828K Buy
36,077
+13,562
+60% +$301K ﹤0.01% 1454
2019
Q3 		$486K Buy
+22,515
New +$483K ﹤0.01% 1633
2019
Q2 		– Sell
-25,945
Closed -$711K – 2634
2019
Q1 		$711K Sell
25,945
-5,392
-17% -$155K 0.01% 1282
2018
Q4 		$842K Sell
31,337
-1,426
-4% -$39.4K 0.01% 992
2018
Q3 		$956K Buy
32,763
+13,770
+73% +$435K 0.01% 1016
2018
Q2 		$594K Buy
+18,993
New +$519K 0.01% 1107

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Squarepoint's RYTM Position: Q2 2026 in Review

Squarepoint increased its Rhythm Pharmaceuticals (RYTM) stake by 61% in Q2 2026, buying an estimated $14.5M and bringing the position to 422,921 shares worth $47M. The position accounts for 0.05% of the portfolio, ranked #355.

Squarepoint first reported a position in RYTM in Q2 2018 and has held it in 22 quarters since. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Squarepoint held 422,921 shares of Rhythm Pharmaceuticals worth $47M as of Q2 2026.
  • Squarepoint bought 159,953 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $14.5M.
  • Rhythm Pharmaceuticals made up 0.05% of Squarepoint's portfolio in Q2 2026, its #355 holding.
  • Squarepoint first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 22 quarters since.
  • 302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.